Sana Biotechnology IncSANA

SANA current price
$2.04-52.87%

Capital at risk.

1W
-13.19%
1M
-23.60%
3M
-56.65%
6M
-68.50%
1Y
-52.87%
MAX
-94.62%
About Sana Biotechnology Inc
Ticker
info
SANA
Trading on
info
NASDAQ
ISIN
info
US7995661045
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Steven D. Harr M.D.
Headquarters
info
188 East Blaine Street, Seattle, WA, United States, 98102
Employees
info
328
Website
info
sana.com
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Metrics
BasicAdvanced
Market cap
info
$522M
P/E ratio
info
-
EPS
info
-$1.40
Dividend Yield
info
0.00%
Beta
info
1.44
Forward P/E ratio
info
0
EBIDTA
info
$-274M
Ex dividend date
info
-
Price & volume
Market cap
info
$522M
Average daily volume
info
1.9M
90-day return
info
-56.65%
30-day return
info
-23.60%
7-day return
info
-13.19%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
1.79
Earnings
EPS
info
-$1.40
EPS estimate (current quarter)
info
-$0.25
EPS estimate (next quarter)
info
-$0.21
EBITDA
info
$-274M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
1.44
52-week High
info
$12.00
52-week Low
info
$1.81
50-day moving average
info
$3.28
200-day moving average
info
$6.08
Short ratio
info
20.07
Short %
info
32.55%
Management effectiveness
ROE (TTM)
info
92.90%
ROA (TTM)
info
31.15%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
223M
Float
info
131M
Insiders %
info
8.63%
Institutions %
info
92.48%
Analyst Insights & forecasts
info

58% Buy

42% Hold

0% Sell

Based on information from 7 analysts.

Average price target

info
$9.40
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.41
-$0.38
7.89%
Q4 • 23Beat
-$0.32
-$0.32
-
Q1 • 24Beat
-$0.32
-$0.28
14.29%
Q2 • 24Beat
-$0.25
-$0.27
7.41%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-50.3M
∞%
Q2 • 24
$-59.9M
0.00%
Q3 • 24
NaN%
19.15%
0.00%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$619M
$279M
45.10%
Q2 • 24
$559M
$267M
47.72%
Q3 • 24
9.58%
4.34%
5.80%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-58.5M
$5.8M
$10.6M
$-71.6M
Q2 • 24
$-51.8M
-
$2.1M
$-55.9M
Q3 • 24
11.48%
-
80.41%
21.91%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Sana Biotechnology Inc share?
Collapse

Sana Biotechnology Inc shares are currently traded for $2.04 per share.

How many shares does Sana Biotechnology Inc have?
Collapse

Sana Biotechnology Inc currently has 223M shares.

Does Sana Biotechnology Inc pay dividends?
Collapse

No, Sana Biotechnology Inc doesn't pay dividends.

What is Sana Biotechnology Inc 52 week high?
Collapse

Sana Biotechnology Inc 52 week high is $12.00.

What is Sana Biotechnology Inc 52 week low?
Collapse

Sana Biotechnology Inc 52 week low is $1.81.

What is the 200-day moving average of Sana Biotechnology Inc?
Collapse

Sana Biotechnology Inc 200-day moving average is $6.08.

Who is Sana Biotechnology Inc CEO?
Collapse

The CEO of Sana Biotechnology Inc is Dr. Steven D. Harr M.D..

How many employees Sana Biotechnology Inc has?
Collapse

Sana Biotechnology Inc has 328 employees.

What is the market cap of Sana Biotechnology Inc?
Collapse

The market cap of Sana Biotechnology Inc is $522M.

What is the P/E of Sana Biotechnology Inc?
Collapse

The current P/E of Sana Biotechnology Inc is null.

What is the EPS of Sana Biotechnology Inc?
Collapse

The EPS of Sana Biotechnology Inc is -$1.40.

What is the PEG Ratio of Sana Biotechnology Inc?
Collapse

The PEG Ration of Sana Biotechnology Inc is null.

What do analysts say about Sana Biotechnology Inc?
Collapse

According to the analysts Sana Biotechnology Inc is considered a buy.